India Equity Research | BFSI - Banks January 6, 2021 **Company Update** 

Refer to important disclosures at the end of this report



Your success is our success

# Strong business growth; asset quality to be key moniterable

#### Bandhan Bank Q3FY21 Business update

- Bandhan Bank has reported healthy AUM growth of 23% yoy/5% qoq to Rs802bn (provisional), which we believe could primarily be driven by better disbursement trends in MFI and mortgages. In our view, Q4 is a seasonally strong quarter for MFI players and Bandhan should also see continued acceleration in growth.
- Deposits grew 30% yoy/8% qoq to Rs711bn, led by strong traction in CASA deposits. CASA ratio improved sharply by 462bps qoq to 42.8% (34% in Q3FY20), which is a positive surprise. Deposits stand at 89% of AUM vs. 84% in Q3FY20.
- Retail deposits grew 38% yoy/13% qoq and are now 81% of overall deposits vs. 76% in Q3FY20. This highlights the bank's strategic focus on building a strong retail deposit franchise, which facilitates asset diversification into secured businesses without much impact on margins.
- Bandhan has not provided update on asset quality, but we expect collection efficiency to trend well, barring some hiccups in Assam due to recent legislation and ensuing elections. The suburban train service too has resumed in WB and collection efficiency in dependent borrowers should gradually improve. The bank has strategically created a strong provisioning buffer (230bps) to absorb any asset quality shocks.
- Apart from the outlook on asset quality in the wake of ensuing elections in key states like Assam/WB, we believe that investors would be keen to understand the promoters' plan to diversify into para-banking activities.
- We have a long-term Buy rating on Bandhan Bank, given its strong liability profile, asset diversification strategy and ability to manage external disruptions given its strong core profitability, provisioning and capital buffers.

#### Exhibit 1: Business update-Q3FY21

Rs bn	3QFY21	3QFY20	YoY	2QFY21	QoQ
Loans AUM	803	655	23%	766	5%
Deposits	712	549	30%	661	8%
CASA	305	188	62%	253	21%
Retail Deposits (%)	577	417	38%	509	13%
Retail to Total Deposits (%)	81	76	600bps	77	500bps
CASA Ratio (%)	43	34	854bps	38	462bps

Source: Company, Emkay Research

Please see our sector model portfolio (Emkay Alpha Portfolio): BFSI-Banks (Page 5)

#### Financial Snapshot (Standalone)

(Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Net income	55,591	78,731	93,309	110,291	134,918
Net profit	19,515	30,237	29,596	40,283	52,354
EPS (Rs)	16.4	18.8	18.4	25.0	32.5
ABV (Rs)	92.6	92.6	107.9	130.8	160.3
RoA (%)	3.9	4.1	3.0	3.4	3.6
RoE (%)	19.0	22.9	17.9	20.4	21.8
PE (x)	24.2	21.1	21.5	15.8	12.2
P/ABV	3.3	3.3	2.8	2.3	1.9

Source: Company, Emkay Research

CMP Rs 396 as of (January 6, 2021)	Target Price Rs 425 (∎) <sup>12 months</sup>
Rating	Upside
BUY (∎)	7.3 %

### Change in Estimates

U		
EPS Chg FY21E/FY22E	E (%)	-/
Target Price change (%	)	NA
Target Period (Months)		12
Previous Reco		BUY
Emkay vs Consensus		
EPS Estim	nates	
	FY21E	FY22E
Emkay	18.4	25.0
Consensus	19.4	26.8
Mean Consensus TP (1	2M)	Rs 420
Stock Details		
Bloomberg Code	BAN	IDHAN IN
Face Value (Rs)		10
Shares outstanding (mn	)	1,610
52 Week H/L		526 / 152
M Cap (Rs bn/USD bn)	6	38 / 8.72
Daily Avg Volume (nos.)	) 10	0,860,580
Daily Avg Turnover (US	\$ mn)	52.7
Shareholding Pattern	Son '20	
Promoters	Sep 20	40.0%
Fils		32.2%
DIIs		5.8%
Public and Others		21.9%
		21.970
Price Performance		
(%) 1M 3I	M 6M	12M
Absolute 1 2	9 11	(20)
Rel. to Nifty (6)	7 (16)	) (33)
Relative price chart		
525 Rs		% [ 10
450 -		4
375 -		<u></u> -18
300 -	hmm	-32
225 -		46
150		-60
Dec-19Feb-20 Apr-20 Jun-20	Aug-20 Oct	
Bandhan Bank (LHS)	Rel	to Nifty (RHS)
Source: Bloomberg This report is solely produced following person(s) are respon production of the recommend	nsible for t	Global. The he
Anand Dama		
anand.dama@emkayglo	bal.com	
+91 22 6624 2480		
Mayank Agarwal mayank agarwal@emka	valobal r	com

mayank.agarwal@emkayglobal.com

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## Key Financials (Standalone)

#### **Income Statement**

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Net interest income	44,961	63,239	76,345	91,221	113,202
Other income	10,630	15,492	16,965	19,070	21,716
Fee income	5,990	7,995	9,645	11,285	13,542
Net income	55,591	78,731	93,309	110,291	134,918
Operating expenses	18,110	24,265	27,874	33,026	39,946
Pre provision profit	37,482	54,466	65,435	77,266	94,972
PPP excl treasury	37,104	53,332	64,880	76,683	94,360
Provisions	7,351	13,932	25,869	23,411	24,980
Profit before tax	30,131	40,534	39,566	53,854	69,992
Тах	10,616	10,297	9,971	13,571	17,638
Tax rate	35	25	25	25	25
Profit after tax	19,515	30,237	29,596	40,283	52,354

#### **Balance Sheet**

Y/E Year End (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Equity	11,931	16,102	16,104	16,104	16,104
Reserves	100,087	135,852	163,080	200,140	248,306
Net worth	112,017	151,955	179,184	216,244	264,410
Deposits	432,316	570,815	717,492	924,073	1,195,836
Borrowings	3,614	162,192	147,997	142,241	129,596
Total liabilities	564,417	917,178	1,071,032	1,316,417	1,627,787
Cash and bank	38,792	63,449	76,139	91,367	109,640
Investments	100,375	153,518	176,013	210,968	261,632
Loans	396,434	666,299	784,443	990,846	1,238,692
Others	6,270	10,144	11,372	14,100	16,798
Total assets	564,417	917,178	1,071,032	1,316,417	1,627,787

#### Key Ratios (%)

Y/E Year End	FY19	FY20	FY21E	FY22E	FY23E
NIM	9.1	8.7	7.8	7.8	7.8
Non-II/avg assets	2.1	2.1	1.7	1.6	1.5
Fee income/avg assets	1.2	1.1	1.0	0.9	0.9
Opex/avg assets	3.6	3.3	2.8	2.8	2.7
Provisions/avg assets	1.5	1.9	2.6	2.0	1.7
PBT/avg assets	6.0	5.5	4.0	4.5	4.8
Tax/avg assets	2.1	1.4	1.0	1.1	1.0
RoA	3.9	4.1	3.0	3.4	3.6
RoAE	19.0	22.9	17.9	20.4	21.8
GNPA (%)	2.0	1.5	3.0	2.7	2.4
NNPA (%)	0.6	0.6	0.9	0.8	0.7
Per Share Data (Rs)	FY19	FY20	FY21E	FY22E	FY23E
EPS	16.4	18.8	18.4	25.0	32.5
BVPS	93.9	94.4	111.3	134.3	164.2
ABVPS	92.6	92.6	107.9	130.8	160.3
DPS	2.1	0.0	1.5	2.0	2.6
Valuations (x)	FY19	FY20	FY21E	FY22E	FY23E
PER	24.2	21.1	21.5	15.8	12.2
P/BV	4.3	4.3	3.7	3.0	2.5
P/BV P/ABV	4.3 3.3	4.3 3.3	3.7 2.8	3.0 2.3	
					2.5 1.9 5.1

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

India Equity Research | Company Update

Growth (%)	FY19	FY20	FY21E	FY22E	FY23E
NII	48.3	40.7	20.7	19.5	24.1
PPOP	54.2	45.3	20.1	18.1	22.9
PAT	45.0	54.9	(2.1)	36.1	30.0
Loans	33.4	68.1	17.7	26.3	25.0

Quarterly (Rs mn)	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21
NII	15,290	15,402	15,402	15,402	15,402
NIM(%)	8.2	7.9	8.1	8.2	8.0
PPOP	13,069	12,638	13,809	13,129	12,447
PAT	9,718	7,310	3,775	2,785	5,372
EPS (Rs)	6.04	4.54	2.34	1.73	3.34
Source: Company, Emkay Research					
Shareholding Pattern (%)	Dec-19	Mar-20	Jun-20	Aug-20	Sep-20
Promoters	61.0	61.0	61.0	40.0	40.0
FIIs	13.9	13.1	14.5	27.3	32.2
DIIs	4.1	3.6	2.4	4.9	5.8
Public and Others	21.0	22.4	22.1	27.8	21.9
Source: Capitaline					

Source: Capitaline

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


#### RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
3-Nov-20	308	425	12m	Buy	Anand Dama
7-Oct-20	315	390	12m	Buy	Anand Dama
26-Sep-20	265	390	12m	Buy	Anand Dama
16-Jul-20	343	390	12m	Hold	Anand Dama
13-May-20	252	255	12m	Hold	Anand Dama
11-Apr-20	192	262	12m	Buy	Anand Dama
5-Apr-20	182	262	12m	Buy	Anand Dama
14-Jan-20	519	650	12m	Buy	Anand Dama
24-Oct-19	571	675	12m	Buy	Anand Dama
9-Oct-19	481	625	12m	Buy	Anand Dama
23-Sep-19	527	625	12m	Buy	Anand Dama
13-Sep-19	455	600	12m	Buy	Anand Dama
19-Jul-19	527	660	12m	Buy	Anand Dama
2-May-19	625	690	12m	Buy	Anand Dama
20-Mar-19	498	620	12m	Buy	Anand Dama

Source: Company, Emkay Research

#### **RECOMMENDATION HISTORY CHART**







#### Analyst: Anand Dama

**Contact Details** 

anand.dama@emkayglobal.com +91 22 6624 2480

Sector

-----

Banks

Analyst bio

Anand Dama is a CA, CPM (ICFAI) with total 12 years of research experience, in addition to 3 years in the finance/rating industry. His team currently covers 21 banks and 15 stocks in the NBFC/Insurance space.

# Emkay Alpha Portfolio – BFSI-Banks

EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
BFSI-Banks	20.91	20.91	0.0%	0	100.00
Axis Bank	2.21	2.36	7%	15	11.29
AU Small Finance Bank	0.23	0.20	-13%	-3	0.97
Bandhan Bank	0.37	0.53	44%	16	2.54
Bank of Baroda	0.11	0.11	1%	0	0.52
Canara Bank	0.09	0.00	-100%	-9	0.00
City Union Bank	0.17	0.17	-1%	0	0.81
DCB Bank	0.00	0.00	NA	0	0.00
Equitas Small Finance Bank	0.00	0.00	NA	0	0.00
Federal Bank	0.18	0.18	0%	0	0.87
HDFC Bank	7.33	7.51	3%	18	35.91
ICICI Bank	4.68	4.88	4%	20	23.33
Indian Bank	0.00	0.00	NA	0	0.00
Indusind Bank	0.66	0.76	15%	10	3.63
Karur Vysya Bank	0.00	0.00	NA	0	0.00
Kotak Mahindra Bank	3.23	2.60	-19%	-63	12.45
Punjab National Bank	0.11	0.00	-100%	-11	0.00
RBL Bank	0.16	0.14	-14%	-2	0.65
State Bank of India	1.36	1.47	8%	11	7.03
Ujjivan Small Finance Bank	0.00	0.00	NA	0	0.00
Union Bank of India	0.03	0.00	-100%	-3	0.00
Yes Bank	0.00	0.00	NA	0	0.00
Cash	0.00	0.00	NA	0	0.00

Source: Emkay Research

\* Not under coverage: Equal Weight

High Conviction/Strong Over Weight

#### Sector portfolio NAV

	Base					Latest
	1-Apr-19	7-Jan-20	7-Jul-20	6-Oct-20	4-Dec-20	5-Jan-21
EAP - BFSI-Banks	100.0	108.6	78.3	79.9	103.4	108.7
BSE200 Neutral Weighted Portfolio (ETF)	100.0	104.7	77.3	78.5	101.7	106.9


\*Performance measurement base date 1st April 2019 | Source: Emkay Research

#### Price Performance (%)

	1m	3m	6m	12m
EAP - BFSI-Banks	5.1%	36.1%	38.8%	0.1%
BSE200 Neutral Weighted Portfolio (ETF)	5.1%	36.2%	38.3%	2.2%

Source: Emkay Research





Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

#### **Emkay Rating Distribution**

Expected Return within the next 12-18 months.
Over 15%
Between -5% to 15%
Below -5%

Completed Date: 07 Jan 2021 02:20:41 (SGT) Dissemination Date: 07 Jan 2021 02:21:41 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or has associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of January 6, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
- Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of January 6, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the January 6, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the January 6, 2021

RESTRICTIONS ON DISTRIBUTION		
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.	
Australia	This report is not for distribution into Australia.	
Hong Kong	This report is not for distribution into Hong Kong.	
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.	
Malaysia	This report is not for distribution into Malaysia.	
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.	
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.	
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.	
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.	
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.	
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.	
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.	

#### Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com